Science Translational Medicine: UBIVE publication on Lassa fever vaccine
Lassa fever is a major public health issue in Western Africa. At least seven lineages co-circulate and are responsible for yearly outbreaks causing thousands of death. Several Lassa fever vaccines are being developed but so far none has demonstrated efficacy against highly divergent Lassa virus strains or was shown to induce long-lasting immunity for up to a year in non-human primates. We have developed MeV-NP, a measles based vaccine expressing two antigens of Lassa virus, the glycoprotein and the nucleoprotein. In this study, we show that MeV-NP protects non-human primates against strains from 3 different lineages of Lassa virus and induces long-term immunity able to protect monkeys against a Lassa virus challenge more than a year after a single shot. This work thus supports further development of MeV-NP as a Lassa fever vaccine.
BY MATHIEU MATEO, STÉPHANIE REYNARD, ALEXANDRA JOURNEAUX, CLARA GERMAIN, JIMMY HORTION, XAVIER CARNEC, CAROLINE PICARD, NICOLAS BAILLET, VIRGINIE BORGES-CARDOSO, OTHMANN MERABET, AUDREY VALLVE, STÉPHANE BARRON, OPHÉLIE JOURJON, ORIANNE LACROIX, AURÉLIE DUTHEY, MANON DIRHEIMER, GREGORY JOUVION, PIERRE-HENRI MOREAU, LYNE FELLMANN, CAROLINE CARBONNELLE, HERVÉ RAOUL, FRÉDÉRIC TANGY, SYLVAIN BAIZE
SCIENCE TRANSLATIONAL MEDICINE 09 JUN 2021